Putting science
at the heart of development
A rising generics industry in developing nations is helping secure access to cheap drugs for the world's poor. But controversies over patent rules could divert investment from already neglected diseases.
(Photo credit: WHO/TDR/Crump)
Opinions and Analysis
Africa Analysis: Continent must back TB research drive
International bodies are offering true research opportunities, but African funding is needed to prepare the ground, writes Linda Nordling.
Failing vaccine strategies need to be revamped
New approaches are needed to reverse the trend of disappointing vaccines against HIV/AIDS, tuberculosis and malaria, argues biotech expert Thomas Egwang.
New R&D model to promote access to drugs
16 November 2012
|
ES
Source: Boletín de la OMS
Policy Briefs
Controlling insect pests with GM technology
Genetically modified insects provide a new method for controlling insect-borne diseases and agricultural insect pests.
8 July 2010
|
EN
Source: The Parliamentary Office of Science and Technology
Policies to tackle HIV/AIDS
Reducing the global burden of HIV/AIDS relies on increased funding, more research and targeted prevention strategies.
1 December 2009
|
EN
Source: Health Affairs
News and Features
India develops cheap rotavirus vaccine
A cheap vaccine developed in India against rotavirus could add substantially to protection against diarrhoea.
16 May 2013
|
EN
WHO approves synthetic source of artemisinin
GM-produced artemisinin is deemed to be comparable in quality to the plant-derived version, but should be cheaper to produce.
13 May 2013
|
EN
Vaccine against Chagas disease shows effectiveness
16 April 2013
|
ES
Indian court's Novartis ruling keeps door to cheap drugs open
2 April 2013
|
EN
.jpg){kind=spacer}
